Adding pre-emptive anticholinergics to antipsychotics: Is it justified?
Anti-psychotics are the mainstay of treatment for Schizophrenia and psychotic disorders. Historically, anticholinergics have been prescribed to prevent or treat extrapyramidal side effects (EPS) associated with first-generation antipsychotics (FGAs). Even though newer antipsychotics are associated w...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Industrial Psychiatry Journal |
| Subjects: | |
| Online Access: | http://www.industrialpsychiatry.org/article.asp?issn=0972-6748;year=2022;volume=31;issue=2;spage=370;epage=373;aulast=Chatterjee |
| _version_ | 1828344788826456064 |
|---|---|
| author | Kaushik Chatterjee Ankit Dangi Rachit Sharma Prateek Yadav Vinay Singh Chauhan Jyoti Prakash |
| author_facet | Kaushik Chatterjee Ankit Dangi Rachit Sharma Prateek Yadav Vinay Singh Chauhan Jyoti Prakash |
| author_sort | Kaushik Chatterjee |
| collection | DOAJ |
| description | Anti-psychotics are the mainstay of treatment for Schizophrenia and psychotic disorders. Historically, anticholinergics have been prescribed to prevent or treat extrapyramidal side effects (EPS) associated with first-generation antipsychotics (FGAs). Even though newer antipsychotics are associated with markedly lower rates of EPS, concurrent anticholinergic use remains high. Use of these medications has potential for long-term side effects, worsening of EPS and poor adherence. We have briefly discussed the limited association between second-generation antipsychotics (SGAs) and EPS, the efficacy of anticholinergics for different types of EPS, and summarized various national and international guidelines on the subject. In conclusion, there is no evidence for prophylactic use of anticholinergics with antipsychotics. Clinicians need to guard against this tendency to be unduly cautious. |
| first_indexed | 2024-04-14T00:02:27Z |
| format | Article |
| id | doaj.art-c04f9709d4064d93b5cb0ed849566f2c |
| institution | Directory Open Access Journal |
| issn | 0972-6748 0976-2795 |
| language | English |
| last_indexed | 2024-04-14T00:02:27Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Industrial Psychiatry Journal |
| spelling | doaj.art-c04f9709d4064d93b5cb0ed849566f2c2022-12-22T02:23:39ZengWolters Kluwer Medknow PublicationsIndustrial Psychiatry Journal0972-67480976-27952022-01-0131237037310.4103/ipj.ipj_269_21Adding pre-emptive anticholinergics to antipsychotics: Is it justified?Kaushik ChatterjeeAnkit DangiRachit SharmaPrateek YadavVinay Singh ChauhanJyoti PrakashAnti-psychotics are the mainstay of treatment for Schizophrenia and psychotic disorders. Historically, anticholinergics have been prescribed to prevent or treat extrapyramidal side effects (EPS) associated with first-generation antipsychotics (FGAs). Even though newer antipsychotics are associated with markedly lower rates of EPS, concurrent anticholinergic use remains high. Use of these medications has potential for long-term side effects, worsening of EPS and poor adherence. We have briefly discussed the limited association between second-generation antipsychotics (SGAs) and EPS, the efficacy of anticholinergics for different types of EPS, and summarized various national and international guidelines on the subject. In conclusion, there is no evidence for prophylactic use of anticholinergics with antipsychotics. Clinicians need to guard against this tendency to be unduly cautious.http://www.industrialpsychiatry.org/article.asp?issn=0972-6748;year=2022;volume=31;issue=2;spage=370;epage=373;aulast=Chatterjeeanticholinergicsantipsychoticsextrapyramidal symptomsprophylaxis |
| spellingShingle | Kaushik Chatterjee Ankit Dangi Rachit Sharma Prateek Yadav Vinay Singh Chauhan Jyoti Prakash Adding pre-emptive anticholinergics to antipsychotics: Is it justified? Industrial Psychiatry Journal anticholinergics antipsychotics extrapyramidal symptoms prophylaxis |
| title | Adding pre-emptive anticholinergics to antipsychotics: Is it justified? |
| title_full | Adding pre-emptive anticholinergics to antipsychotics: Is it justified? |
| title_fullStr | Adding pre-emptive anticholinergics to antipsychotics: Is it justified? |
| title_full_unstemmed | Adding pre-emptive anticholinergics to antipsychotics: Is it justified? |
| title_short | Adding pre-emptive anticholinergics to antipsychotics: Is it justified? |
| title_sort | adding pre emptive anticholinergics to antipsychotics is it justified |
| topic | anticholinergics antipsychotics extrapyramidal symptoms prophylaxis |
| url | http://www.industrialpsychiatry.org/article.asp?issn=0972-6748;year=2022;volume=31;issue=2;spage=370;epage=373;aulast=Chatterjee |
| work_keys_str_mv | AT kaushikchatterjee addingpreemptiveanticholinergicstoantipsychoticsisitjustified AT ankitdangi addingpreemptiveanticholinergicstoantipsychoticsisitjustified AT rachitsharma addingpreemptiveanticholinergicstoantipsychoticsisitjustified AT prateekyadav addingpreemptiveanticholinergicstoantipsychoticsisitjustified AT vinaysinghchauhan addingpreemptiveanticholinergicstoantipsychoticsisitjustified AT jyotiprakash addingpreemptiveanticholinergicstoantipsychoticsisitjustified |